Commerzbank Aktiengesellschaft FI Sells 7,905 Shares of Thermo Fisher Scientific Inc. $TMO

Commerzbank Aktiengesellschaft FI trimmed its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 11.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 64,033 shares of the medical research company’s stock after selling 7,905 shares during the period. Commerzbank Aktiengesellschaft FI’s holdings in Thermo Fisher Scientific were worth $31,057,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of TMO. Highline Wealth Partners LLC grew its position in shares of Thermo Fisher Scientific by 126.9% in the 3rd quarter. Highline Wealth Partners LLC now owns 59 shares of the medical research company’s stock worth $29,000 after buying an additional 33 shares during the last quarter. Capital A Wealth Management LLC boosted its holdings in Thermo Fisher Scientific by 825.0% in the second quarter. Capital A Wealth Management LLC now owns 74 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 66 shares in the last quarter. DiNuzzo Private Wealth Inc. increased its position in Thermo Fisher Scientific by 406.7% during the 2nd quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 61 shares during the period. HighMark Wealth Management LLC lifted its position in shares of Thermo Fisher Scientific by 140.6% in the 2nd quarter. HighMark Wealth Management LLC now owns 77 shares of the medical research company’s stock worth $31,000 after purchasing an additional 45 shares during the period. Finally, Howard Hughes Medical Institute bought a new stake in shares of Thermo Fisher Scientific during the 2nd quarter valued at about $33,000. 89.23% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Barclays raised their price objective on shares of Thermo Fisher Scientific from $585.00 to $625.00 and gave the stock an “overweight” rating in a report on Thursday, October 23rd. Hsbc Global Res upgraded Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research note on Monday, December 1st. Redburn Partners set a $580.00 price target on Thermo Fisher Scientific in a research note on Wednesday, October 8th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Thermo Fisher Scientific in a research report on Thursday, October 23rd. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Friday, January 9th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $625.47.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, COO Michel Lagarde sold 32,000 shares of the stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $583.39, for a total transaction of $18,668,480.00. Following the sale, the chief operating officer directly owned 65,480 shares in the company, valued at approximately $38,200,377.20. This trade represents a 32.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Michael D. Shafer sold 10,725 shares of the business’s stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $600.00, for a total value of $6,435,000.00. Following the completion of the transaction, the executive vice president owned 18,731 shares of the company’s stock, valued at $11,238,600. This represents a 36.41% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 131,767 shares of company stock worth $76,467,793 in the last three months. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO opened at $625.42 on Friday. The business has a fifty day moving average price of $590.88 and a 200-day moving average price of $531.60. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11. The company has a market capitalization of $234.98 billion, a PE ratio of 36.13, a PEG ratio of 4.12 and a beta of 0.91. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, beating the consensus estimate of $5.50 by $0.29. The company had revenue of $11.12 billion for the quarter, compared to the consensus estimate of $10.90 billion. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. Thermo Fisher Scientific’s revenue for the quarter was up 4.9% on a year-over-year basis. During the same period in the prior year, the firm posted $5.28 EPS. As a group, equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, January 15th. Investors of record on Monday, December 15th were given a dividend of $0.43 per share. The ex-dividend date of this dividend was Monday, December 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 9.94%.

Thermo Fisher Scientific declared that its board has authorized a stock repurchase plan on Thursday, November 6th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical research company to repurchase up to 2.4% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s leadership believes its shares are undervalued.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.